- Gene signature
for aggressive form of prostate cancer identified by researchers from
Princess Margaret Cancer Centre.
- It would aid in
identifying prostate cancer patients with poor prognosis
- The researcher
team showed that BRCA-2 associated prostate cancer shows poor prognosis due to faulty
DNA repair mechanism
research team from Canada has uncovered a genetic fingerprint, which could help identify a vigorous form of prostate
that spreads aggressively after radiotherapy or surgery. This
form of cancer is found to occur in 30% of prostate cancer patients.
study was published in the journal Nature
and would aid in developing a more personalized treatment plan for patients
with prostate cancer, says Dr. Robert Bristow who is the principal investigator
of the study and a scientist at the Princess Margaret Cancer Centre.
‘The newly identified genetic fingerprint for prostate cancer would aid in providing individual specific care’
research team analyzed the cancers of 500 Canadian men who had non-inherited
prostate cancer that was localized. Dr. Bristow said they used specialized DNA
sequencing techniques that focused on the genes associated with prostate cancer
to understand why the different types are so varied.
genetic fingerprints that the scientists identified aided in
- Discerning men
who were well after radiotherapy or even surgery and men who had an early
spread of the disease which was out of the prostate gland.
- Provided a new
identification or a benchmark about response to treatment.
- Provided clues
for better treatment for men with certain types of prostate cancer.
scientists believe that the next step in this study would be to identify a
molecular diagnostic tool which can be used in the clinic. Five-hundred
more men with prostate cancer will be tested over the next 2
to 3 years and Dr. Bristow said, "It
is an exciting era in prostate cancer research. We will soon be able to
identify in the clinic the exact genetic state of a man's cancer and react on a
patient-to-patient basis to cure more men worldwide."
The research team that conducted this study was led by Dr. Bristow and Dr. Boutros, who together head the Canadian prostate cancer genome network (CPC-Gene), the world's leading sequencing program on prostate cancer, and have worked on prior discoveries.
research team first identified the molecular portrait of prostate cancer that
was multi-focal with a new gene subgroup. This study was published in the
journal Nature Genetics
on May 2015. Another previous study dealt with
the development of a genetic test that was designed to identify men who were at
a higher risk to develop prostate cancer and for a higher propensity for
recurrence following radiotherapy
Bristow added that most men diagnosed with prostate cancer had localized
disease that was potentially curable. However, 200,000 and more men die of
prostate cancer every year. He further added,
"The richness of information in our genetic findings today will enable us to
further sort individual patients into appropriate groups of risk for spread of
their disease and effect cures in men who otherwise might have been
Prostate Cancer and
study that was published by the same authors recently dealt with how BRCA-2
associated disease was lethal in certain cases in men when the mutation in the
gene leads to fault in DNA damage repair.
discovery of BRCA1-2 mutations was initially
associated with mutations that played a vital role in the growth and
progression of breast cancer as well as ovarian cancer. There have been many
studies that have detailed the importance of the BRCA genes in the various
forms of cancer. Some families show a higher inclination for prostate cancer
which has been associated with BRCA1-2
gene germline mutation. Studies show that the presence of certain mutations in
both BRCA1 and 2 mutations indicate poor prognosis of the patient with low
rates of survival and indicate an aggressive pattern of the disease.
studies show that some forms of prostate cancer have poor diagnosis and are
associated with hereditary factors. This is consistent with the studies on
BRCA1 and BRCA2 mutations. The association between prostate cancer and BRCA-2 is consistent within research. There are also other studies that
have found that men who carry mutations in BRCA-2 have an elevated risk of developing prostate cancer while male
carriers of BRCA-1 mutation are known to
have a moderately higher risk of getting prostate cancer when compared with
people without the mutations. The study shows that men with the mutation in
the BRCA-2 gene have a 7 times
higher risk of developing prostate cancer than men without the mutation.
BRCA-2 gene is a very important gene in cancer growth and development but
it's significance among men has
only been recently highlighted. The research team
found that men with the mutation in BRCA-2 showed poor prognosis due to a faulty repair DNA repair mechanism.
The genetic fingerprints
that have been identified in these research studies aid in identifying patients
at higher risk of having an aggressive form of prostate cancer and will aid in
tailoring treatment accordingly, paving the way for personalized care.